From 2025 to 2035, the infertility drugs market is expected to show a 6.3% compound annual growth rate (CAGR), driven by rising incidence of infertility, new technology innovations in reproductive medicine, and increasing applications of assisted reproductive technologies (ART). Estimated to be valued at about USD 4,172 million in 2025, the Compound Annual Growth Rate (CAGR) for the market is projected to reach up to USD 7,692 million by the year 2035, while witnessing a considerable escalation during the assessment period.
A few things are driving changes in the market. One of the things behind it is the rise of infertility because of stress, lifestyle changes and delayed births. Pharma is broadening their range of products to include ART. Gonadotropins (e.g., Follitropin alfa) and Clomiphene citrate are appearing as a viable first-line treatment for ovulatory disorders in women, while men may receive hormone-based therapies, such as human chorionic gonadotropin (hCG). Hormonal treatments have side effects and higher price tags pose a challenge for affordability of treatments and businesses have reached a stage where it is high time to invest in the research to find a better and a safer alternative.
| Metric | Value |
|---|---|
| Industry Size (2025E) | USD 4,172 million |
| Industry Value (2035F) | USD 7,692 million |
| CAGR (2025 to 2035) | 6.3% |
By the type of drug, the market can be classified into gonadotropins, selective estrogen receptor modulators (SERMs), dopamine agonists and aromatase inhibitors. Human gonadotropins such as Menotropins, recombinant FSH play an important role in stimulating follicular development during assisted reproductive technologies (ART) such as IVF. Clomiphene citrate belongs to the SERM class and works to balance estrogen levels and induce ovulation in some women.
Dopaminergic agents, darbesagiline (cabergoline, a long-acting agent), are prescribed for infertility due to hyperprolactinemia, and lately aromatase inhibitors (for instance, letrozole) have become preferable as medications for ovulation induction. The demand for infertility drugs is most in ART clinics, hospitals and homecare setting as couples are increasingly choosing personalized treatments for fertility.
Explore FMI!
Book a free demo
The high availability of ART clinics and massive pharmaceutical research in this area is the main driver of the North America infertility drugs market. Fertility treatments are on the rise in the USA and Canada as more people are aware of infertility, more procedures are insured Targeted drugs: GnRH antagonists or newer medications used for controlled ovarian stimulation are some advanced drugs which stimulates the market. In addition, biotech firms are more often developing bioidentical hormone therapies that have less severe side effects and are being sought by patients looking for more natural fertility methods.
However, Europe has a larger share of the market and high demand from Germany, France, and the United Kingdom. The Infertility drugs market in the region is driven primarily by government initiatives undertaken by a number of countries in the region supporting ART procedures and advocating reproductive health research to other countries, including the UK where the NHS of the UK also covers fertility treatments, providing access to drugs such as Letrozole and Clomiphene citrate.
To further compound the situation, Germany wants to reinforce the biosimilars of infertility medicines in major pharmaceutical companies in Germany so that the medicines become much more affordable. In the European Union, strict regulatory policy affecting hormonal drugs stimulates the development of alternative safer drugs with minimal side effect.
Asia-Pacific has been projected to see the fastest-growing infertility drugs market, due to increasing rates of infertility, growing medical tourism, and advancing healthcare infrastructure. Shifting lifestyles and delayed pregnancies are driving up demand for ART treatments in countries in Asia, including China, India, Japan and South Korea. India’s pharmaceutical industry is also a major supplier of generic infertility medicine, which helps keep treatment costs low.
China seeks new frontiers in treatment of male infertility issues: The country’s fertility clinics are also seeking novel treatments in the battle against male infertility, including stem cell-based fertility treatments. 21,25]However, cultural stigma attached to infertility treatments is a hindrance in some regions, and affects market penetration.
Challenge
High Cost of Infertility Treatments
Infertility treatments like assisted reproductive technologies or ART procedures and the drugs used in these procedures are expensive treatments, which create a major burden for patients. Hormonal injections, gonadotropins and IVF cycles cost thousands of dollars, making it hard for many couples to afford.
In addition, the lack of adequate reimbursement policies in many countries creates a financial hurdle that can limit access to treatment. Pharma companies are on notice to think creatively and propose more cost-effective substitutes that all people can access to get treatment to more of the population such as oral infertility drugs.
Opportunity
Advancements in Personalized Medicine
A new trend in the infertility drugs market is the shift of fertility treatments towards personalized medicine. So health care companies are investing billions in precision medicine approaches that tailor infertility treatments based on genetic profiles and hormone levels.
For example, recombinant hormone therapies and AI-based reproductive prediction software are some approaches developed to reduce side effects and improve treatment efficacy. Studies of other kinds of therapies, including herbal-based infertility drugs and microbiome-targeted treatments, are also receiving more attention as patients inquire about natural and holistic approaches.
Arising from increasing infertility rates, a higher adoption of ART and an evolution in pharmaceutical formulations, the infertility drugs market expanded with considerable momentum between 2020 and 2024.
The COVID-19 pandemic temporarily shut down fertility treatments, but a post-pandemic rebound triggered a surge in demand for both IVF and fertility medications. New and innovative drug delivery systems, such as long-acting injectables and sublingual tablets that were introduced in order to bolster patient compliance and treatment outcomes.
Looking to 2025 and subsequent years, the market will be impacted by persistent advancements of reproductive genetics and research into AI-assisted fertility treatment plans and stem cell therapy.
Hormone Free infertility solutions and Biodegradable drug formulations for fertility care- in 2024, you will witness a lot of hormone free infertility solutions and biodegradable drug formulations for fertility care. Growing acceptance of such methods egg and sperm freezing, for instance will also drive demand for specialized drugs for infertility that vary by the stage of reproduction.
Market Shifts: A Comparative Analysis (2020 to 2024 vs. 2025 to 2035)
| Market Shift | 2020 to 2024 |
|---|---|
| Regulatory Landscape | Regulatory bodies such as the FDA and EMA concentrated on sanctioning approval of assisted reproduction medicines with unequivocal evidence of safety and efficacy. Off-label prescribing policies were relaxed but were subjected to scrutiny. |
| Technological Advancements | Gonadotropin preparations developed, better performance with fewer side effects. Stem cell-derived fertility drug research got concentrated. |
| Assisted Reproductive Technology (ART) Integration | ART centers employed commonly available standard hormonal medicine such as Clomid and gonadotropins to trigger ovulation. |
| Male Infertility Treatments | Limited options for male infertility treatment were available, and surgery and lifestyle modification were the major treatment modalities. |
| Market Expansion in Emerging Regions | The developing world saw a rise in demand for drugs used to treat infertility as awareness increased and urbanization accelerated, but access was not easy. |
| Consumer Preferences & Trends | Women opted for natural fertility drugs and weaker hormonal drugs because of side effect fear. |
| Production & Supply Chain Dynamics | The COVID-19 pandemic disrupted pharmaceutical drug supply chains, resulting in drug shortages and ART procedure delay. |
| Market Growth Drivers | Rises in maternal age, lifestyle changes, and environmental influences fuelled demand for fertility drugs. |
| Market Shift | 2025 to 2035 |
|---|---|
| Regulatory Landscape | Governments introduce tighter controls to guarantee long-term safety of infertility medication. Greater control brings about the development of biosimilars and customized reproductive medicine. |
| Technological Advancements | Fertility treatments using AI optimize drug regimens, minimizing cycle failure. Nanotechnology-enabled drug delivery systems enhance bioavailability and minimize hormone dosage needs. |
| Assisted Reproductive Technology (ART) Integration | Genetic screening combined with infertility medication in next-generation ART enables customized treatment protocols based on patient DNA profiles. |
| Male Infertility Treatments | New androgen receptor modulators and gene therapies increase male fertility, broadening drug choice beyond conventional hormone therapy. |
| Market Expansion in Emerging Regions | Subsidies from governments and insurance cover in developing markets provide affordable access to high-end fertility treatments, fueling mass adoption of infertility drugs. |
| Consumer Preferences & Trends | Patients adopt evidence-based fertility treatment, preferring AI-driven fertility monitoring with targeted drug regimens for superior success rates. |
| Production & Supply Chain Dynamics | Decentralized pharmaceutical production and regionalized production centers minimize reliance on sole-source providers, ensuring steady market expansion. |
| Market Growth Drivers | Personalized medicine, biotechnology advances, and digital health solutions drive market growth, with increased success rates for fertility treatment. |
The increasing number of couples undertaking In-Vitro Fertilization (IVF) and the higher success rates of IVF procedures in recent years have been identified as the key drivers of growth for the US infertility drugs market. Increasing average age of mother and higher infertility rates from lifestyle conditions, including stress and obesity, will lead to demand for advanced fertility drugs.
As we move closer toward 2024 and beyond, the regulatory environment will continue to shift in favour of personalized reproductive medicine, which will no doubt have further implications for the market. AI will also be used in fertility clinics, where it will make treatment faster and better than it is possible today; alongside with better hormone therapies. In addition, the push by the USA government to make insurers cover fertility treatments will lower the cost of ART procedures.
In-demand Ovulation Induction Drugs: Most of the patients are reported to require Ovulation Induction by USA fertility clinics. More advanced formulations of gonadotropins, along with precision dosing, will reduce the number of treatment cycles and enhance conception rates. Approved new treatments targeting sperm motility and function are also expected to spur growth in male infertility drug adoption.
| Country | CAGR (2025 to 2035) |
|---|---|
| USA | 6.2% |
Government support on fertility drugs, centering of reproductive technology, and changing social paradigms are key elements driving the growth of the UK infertility drugs market. Investment by the National Health Service (NHS) in ART has made treatment increasingly available for infertility couples.
So some British pharmaceutical firms are investing in the development of non-hormonal methods, like anti-inflammatory drugs that make the endometrium more receptive. Hormone stimulation medication usage to improve embryo selection alongside time-lapse imaging of embryos also predicts greater success.
| Country | CAGR (2025 to 2035) |
|---|---|
| UK | 6.8% |
Increased adoption of assisted reproductive technology (ART), improved insurance coverage and government-backed fertility programs aid the growth of the European Union infertility drugs market. The market is largest in Germany, France, and Spain because of a high prevalence of fertility clinics and pharmaceutical innovation.
Regulatory Compliance and Ethical Considerations: The European Medicines Agency (EMA) has your back. A move towards sustainable and ethical reproductive medicine runs parallel to developments in plant-based hormone alternatives and stem-cell-derived fertility treatments.
| Region | CAGR (2025 to 2035) |
|---|---|
| EU | 6.0% |
The birth rate is falling in Japan, but the market for infertility drugs is growing, and the government’s willingness to pay for fertility treatments is fuelling rapid growth. Demand for ART procedures and associated pharmaceuticals is driven by this trend of increasing maternal age in conjunction with cultural changes favouring prolonged periods of non-parenthood.
Japan Advances Male Fertility Treatments: Gene Editing Opens the Door to New Fertility Treatments There are also pharmaceutical companies currently developing next-generation androgen modulators that can enhance sperm production without negative side effects.
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 6.6% |
The overall South Korea Infertility Drugs Market is anticipated to grow at a steady rate in the next five years owing to government-supported fertility programs and increasing awareness among the local population. More recently, the government made ART insurance coverage for these treatments more widely available to couples who are struggling with infertility.
We do not provide medical advice. Machine-learning algorithms use data to visualize and predict drug effectiveness, minimizing the number of failed cycles and increasing pregnancy rates.
| Country | CAGR (2025 to 2035) |
|---|---|
| South Korea | 6.3% |
Due to their very broad application in assisted reproductive technologies (ART) such as in-vitro fertilization (IVF) and intrauterine insemination (IUI) hormone gonadotrophins represent the major class of drugs for the treatment of infertility and therefore have the biggest share of the market. Hormonal agents like follicle-stimulating hormone (FSH) and luteinizing hormone (LH) assist in mediating ovulation in females who are impotent, impulsive, but no clinical infertility is preventive. Due to higher purity and higher consistency, urinary-derived versions have been largely replaced by recombinant versions such as Gonal-F and Follistim that have become more commonly used.
Although effective, gonadotrophins have the potential for side effects (e.g., ovarian hyperstimulation syndrome (OHSS) and must, therefore, be carefully monitored. Nonetheless, increased emphasis on personalized medicine and controlled ovarian stimulation protocols mean they are in high demand in North American and European fertility clinics.
Aromatase inhibitors, especially letrozole, are gaining popularity for use in ovulation induction (OI), particularly in women with polycystic ovary syndrome (PCOS). This natural rise in FSH, due to their ability to inhibit estrogen production, promotes follicular development. Letrozole is becoming the first line agent as compared to older agents like clomiphene citrate creating multiple gestations and poorly receptive endometrium.
Originally developed to treat breast cancer, the off-label use of aromatase inhibitors has surged in infertility treatment, particularly in countries with a high prevalence of PCOS, such as India and China. Aromatase inhibitors are expected to gain greater share in the infertility drug market as approvals broaden and clinical guidelines recommend their use.
Infertility TreatmentClomiphene SERMs, particularly clomiphene citrate, represent a cornerstone in first-line infertility treatment due to their cost-effectiveness and availability. Clomiphene acts as an estrogen receptor blocker, promoting ovulation in women with infrequent cycles. Because the drug is available in many generic forms, it’s also a cheap option in developing areas where women might not have access to high-end fertility treatments.
Despite its advantages, clomiphene's high frequency of multiple pregnancies and possible deleterious effects on the endometrium have made some clinicians consider letrozole[/inline citations] as a first-line therapy. Nevertheless, in cost-sensitive markets, SERMs remain a popular choice for ovulation induction therapy.
In addition, largeuanides like metformin are frequently used in the case of women with PCOS and insulin resistance as an adjunct in infertility management[7]. Metformin works primarily to reverse ovulatory dysfunction by increasing insulin sensitivity and decreasing androgen levels and overall inflammation.
Metformin, while not an infertility drug itself, is often combined with other (eg, clomiphene citrate and letrozole) treatment to stimulate ovulatory response in women with metabolic syndrome. Obesity and insulin resistance have become more and more prevalent and this has further solidified the demand for biguanides in reproductive medicine.
The dominant segment within the infertility drugs market belongs to females since these affect the maximum number of patients through ovulation induction, hormonal regulation, and improvement of endometrium receptivity. Disorders such as PCOS, endometriosis, and age-related decrease in fertility drive the high demand for medications used in female infertility. This segment is also driven by the increasing women who are postponing pregnancies and looking for fertility preservation.
While treatments for male infertility are yet quite limited, increasing research is being devoted to hormonal and non-hormonal therapies. New medication for sperm enhancement via testicular function modulators, among their other innovative area, is expected to broaden the market of male infertility drug in the future.
This renders hospital pharmacies responsible for the second largest share held by the hospital-based pharmacies in the infertility drugs market, in terms of the prescription-based fertility drugs dispensed in hospitals under medical supervision. In a controlled environment, patients receiving IVF-based ART procedures typically obtain their medications from hospital-affiliated fertility clinics, which facilitates adherence with treatment protocols.
Retail pharmacies, too, play a major role, especially in the filling of frequently prescribed oral medications, like clomiphene citrate and metformin. As e-commerce expands, more and more infertility drugs are available for purchase over the internet - a development driven, in part, by the rise of direct-to-consumer healthcare - and urban areas have seen a substantial rise in digital healthcare adoption. As such frameworks expand to cover online prescription fulfillment, this market segment is likely to see further penetration in the coming years.
The market for infertility drugs is highly competitive, with key players in this space include both leading pharmaceutical companies and innovative startups. A few leading companies dominate the market, emphasizing research and development, novel drug formulations and increasing availability of treatments. The companies serve a wide variety of fertility treatments, such as ovulation stimulants and gonadotropins to hormone-based therapies. Reproductive health is a field with a diverse range of established and emerging players working toward innovation.
Market Share Analysis by Company
| Company Name | Estimated Market Share (%) |
|---|---|
| Merck & Co., Inc. | 15-20% |
| Ferring Pharmaceuticals | 12-16% |
| Organon & Co. | 10-14% |
| Bayer AG | 7-11% |
| Abbott Laboratories | 5-9% |
| Other Companies (combined) | 40-50% |
| Company Name | Key Offerings/Activities |
|---|---|
| Merck & Co., Inc. | Develops leading fertility drugs such as Gonal-F (follitropin alfa) and Cetrotide (cetrorelix). Focuses on personalized medicine and digital health solutions. |
| Ferring Pharmaceuticals | Specializes in reproductive medicine with brands like Menopur (menotropins) and Rekovelle (follitropin delta). Invests heavily in fertility preservation research. |
| Organon & Co. | Produces fertility treatments such as Follistim AQ (follitropin beta) and Pregnyl (hCG). Expands into developing countries to improve fertility treatment access. |
| Bayer AG | Manufactures hormone-based thera pies including Clomid (clomiphene citrate) and collaborates on advanced in-vitro fertilization (IVF) research. |
| Abbott Laboratories | Focuses on hormone-related fertility treatments and diagnostic solutions, including advanced ovulation tracking technologies. |
Key Company Insights
Merck & Co., Inc. (15-20%)
The market leader in infertility drugs, Merck & Co., Inc.’s broad range includes Gonal-F, the most widely prescribed ovulation stimulant. With a focus on personalized treatment solutions, the company uses digital health technologies to optimize patient outcomes. Merck: Focus on R&D for improving efficacy and safety profiles; builds global access through partnerships
Ferring Pharmaceuticals (12-16%)
Ferring Pharmaceuticals is a leader in reproductive medicine that delivers innovative fertility products such as Menopur and Rekovelle. The company is committed to advance research on fertility preservation and enhance IVF technologies by partnerships with top clinics. Ferring explains that they also target enhancing hormone-based therapies, thus establishing better experiences for patients.
Organon & Co. (10-14%)
Organon & Co. focuses on women's health and fertility treatments and produces essential medications like Follistim AQ and Pregnyl. Since the company's goal is to make affordable fertility treatments available in emerging markets and raise awareness of the issue. They enable widespread access to treatment by incorporating patient-centric tactics.
Bayer AG (7-11%)
Bayer AG is a leader in hormone-based fertility therapy, especially the use of Clomid, a commonly administered ovulation-stimulating drug. The company works on IVF research, hoping to enhance treatment efficacy and patient safety. Another biotechnology company, Bayer, also puts money into AI-powered fertility tracking, allowing reproductive health to be more accurate.
Abbott Laboratories (5-9%)
Abbott Laboratories focuses on fertility diagnostics and hormone treatments in which the company already has expertise in biotechnology. The firm puts together ovulation tracking technologies to complementary fertility medications, thereby increasing the accuracy of treatment. Abbott's worldwide footprint means it can serve clinics with cutting-edge diagnostics to improve reproductive health outcomes.
Other Substantial Players (40-50% cumulatively)
Besides the top-tier companies mentioned above, there is a number of organizations which by specializing on development of specific products and diversification of their distribution towards regional market segments, impact the global embodiment of the infertility drugs market. These include:
The overall market size for infertility drugs was USD 4,172 million in 2025.
The infertility drugs market is expected to reach USD 7,692 million by 2035.
The increasing prevalence of infertility, advancements in assisted reproductive technologies, and rising awareness about fertility treatments are expected to drive the demand for infertility drugs during the forecast period.
The top 5 countries driving the development of the infertility drugs market are the United States, Germany, United Kingdom, France, and Japan.
On the basis of drug type, the gonadotropins segment commanded a significant share in 2024 and is expected to witness the highest growth over the forecast period.
Cold Relief Roll-On Market Analysis by Application, Distribution Channel, and Region through 2035
At-Home Micronutrient Testing Industry Share, Size, and Forecast 2025 to 2035
Burn Matrix Devices Market Insights - Size, Share & Industry Growth 2025 to 2035
Chlorhexidine Gluconate Dressing Market Outlook - Size, Share & Innovations 2025 to 2035
Chloridometer Market Report Trends- Growth, Demand & Forecast 2025 to 2035
Coagulation Markers Market Trends - Growth, Demand & Forecast 2025 to 2035
Infertility Drugs Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
